Oxaliplatin (Eloxatin) Plus Gemcitabine as First or Second-Line Chemotherapy for Patients With Malignant Pleural or Peritoneal Mesothelioma: A Phase II Clinical Trial.

Trial Profile

Oxaliplatin (Eloxatin) Plus Gemcitabine as First or Second-Line Chemotherapy for Patients With Malignant Pleural or Peritoneal Mesothelioma: A Phase II Clinical Trial.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Jun 2015

At a glance

  • Drugs Gemcitabine (Primary) ; Oxaliplatin (Primary)
  • Indications Mesothelioma
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Jun 2011 Planned end date changed from 1 Apr 2011 to 1 Mar 2013 as reported by ClinicalTrials.gov.
    • 21 Oct 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 12 Mar 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top